Literature DB >> 33740211

Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease.

Jing-Lu Jin1,2, Hui-Wen Zhang1, Ye-Xuan Cao1, Hui-Hui Liu1, Qi Hua3, Yan-Fang Li4, Yan Zhang1, Yuan-Lin Guo1, Na-Qiong Wu1, Cheng-Gang Zhu1, Rui-Xia Xu1, Ying Gao1, Chuan-Jue Cui1, Geng Liu1, Jing Sun1, Qian Dong1, Jian-Jun Li5.   

Abstract

BACKGROUND: Although non-invasive liver fibrosis scores (LFSs) have already been considered as effective tools for estimating cardiovascular risk, their roles in predicting disease severity and cardiovascular event (CVEs) in patients with stable coronary artery disease (CAD) are not comprehensively evaluated. The aim of the present study was to investigate whether non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) are associated with CVEs in a large cohort with long-term follow-up.
METHODS: A cohort of 5143 patients with angiography-proven stable CAD were consecutively enrolled and followed up for CVEs. The degree of coronary severity was assessed using the number of diseased vessels, Gensini, Syntax, and Jeopardy scores. The predictive values of NAFLD-FS and FIB-4 scores to coronary severity, coronary calcification (CAC), and CVEs were assessed, respectively.
RESULTS: During a median follow-up of 7 years, 435 CVEs were recorded. Both NAFLD-FS and FIB-4 were predictors for the presence of CAC. The degree of coronary stenosis was significantly higher in high NAFLD-FS categories while FIB-4 was only positively associated with the number of diseased vessels and Gensini score. In Kaplan-Meier analysis, the patients with intermediate and high NAFLD-FS and FIB-4 had higher risk of CVEs and cardiovascular mortality. In multivariate Cox regression analysis, NAFLD-FS and FIB-4 were independently associated with CVEs [hazard ratio (95% confidence interval): 1.150 (1.063-1.244), p < 0.001 and 1.128 (1.026-1.240), p = 0.012].
CONCLUSION: The current data first indicated that both NAFLD-FS and FIB-4 scores were not only significantly related to coronary severity but also associated with CAC and CVEs. CLINICAL TRIALS REGISTRATION: None.

Entities:  

Keywords:  Calcification; Cardiovascular event; Clinical study; Liver fibrosis score; Non-invasive; Outcome; Prognosis; Risk factor; Stable coronary artery disease; Stenosis

Year:  2021        PMID: 33740211     DOI: 10.1007/s12072-021-10167-w

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  5 in total

1.  High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population.

Authors:  Yukimura Higashiura; Marenao Tanaka; Kazuma Mori; Takuma Mikami; Itaru Hosaka; Hirofumi Ohnishi; Nagisa Hanawa; Masato Furuhashi
Journal:  Eur Heart J Open       Date:  2022-04-16

2.  Non-invasive Liver Fibrosis Scores Are Associated With Recurrence of Postoperative Chronic Subdural Hematoma.

Authors:  Peng Zhang; Hua Wang; Han Bao; Ning Wang; Zhen Chen; Qi Tu; Xiao Lin; Yun Li; Zezheng Zheng; Yu Chen; Linhui Ruan; Qichuan Zhuge
Journal:  Front Neurol       Date:  2022-06-13       Impact factor: 4.086

3.  Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity.

Authors:  Carlo Saitta; Alessia Caruso; Sergio Maimone; Roberto Filomia; Irene Cacciola; Gaia Caccamo; Maria Stella Franzè; Concetta Pitrone; Angela Alibrandi; Michele Gaeta; Giuseppe Mandraffino; Giovanni Squadrito; Giovanni Raimondo
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472

4.  Dyslipidemia and associated cardiovascular risk factors in HIV-positive and HIV-negative patients visiting ambulatory clinics: A hospital-based study.

Authors:  Minyahil A Woldu; Omary Minzi; Ephrem Engidawork
Journal:  JRSM Cardiovasc Dis       Date:  2022-07-21

5.  Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

Authors:  Peter P Toth; Gregory G Schwartz; Stephen J Nicholls; Aziz Khan; Michael Szarek; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Ken Lebioda; Norman C W Wong; Michael Sweeney; Kausik K Ray
Journal:  Am J Prev Cardiol       Date:  2022-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.